Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 21, 2008. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility, specifically detailing changes in their interests in Ordinary Shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider transactions and does not contain financial performance data.
Material Changes and Transaction Details
The filing details the sale or withholding of shares by executives to meet tax liabilities following the vesting of Performance Share Plan (PSP) awards on February 20, 2008.
- Ordinary Shares Sold: Executives sold shares at a price of GBP 11.40 per share. Notable transactions include Mr. A P Witty (13,642 shares), Mr. R M Bondy (13,642 shares), and Mr. J M Clarke (8,482 shares).
- ADSs Withheld: Shares were withheld at a price of $44.75 per ADS. Notable transactions include Dr. JP Garnier (34,117 ADSs), Mr. D M Stout (10,859 ADSs), and Mr. D J Phelan (5,613 ADSs).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the aforementioned share transactions.
Key Facts for Investor Verification
- Verify the total volume of shares sold or withheld by executive directors versus non-executive managers.
- Confirm the share price used for tax calculations (GBP 11.40 for Ordinary Shares; $44.75 for ADSs) against market prices on February 20, 2008.
- Review the specific Performance Share Plan (PSP) vesting terms that triggered these tax liabilities.
- Note that this filing does not reflect the company's broader financial health or operational results.